Materials and methods
General information
Inclusion and exclusion criteria
Examination methods
Image analysis
Pathological examination
Treatment and follow-up
Results
General clinical data
No. | Age (in years) | Symptom | CA125(U/ml) | CA153(U/ml) |
---|---|---|---|---|
1 | 36 | No symptom | 23.9 | 11.6 |
2 | 47 | Abdominal distension, Abdominalgia | 92.7 | 7.7 |
3 | 56 | Abdominal distension, Abdominalgia | 111.3 | 5.8 |
4 | 68 | Lower abdominal discomfort, decreased appetite | 219.4 | 22.9 |
5 | 67 | Abdominal distension, Abdominalgia | 247.4 | 81.5 |
6 | 70 | Abdominal distension, Abdominalgia | 25.4 | 17.5 |
7 | 69 | Abdominal distension, Abdominalgia | 94.3 | 32.2 |
8 | 65 | Abdominal distension, Abdominalgia | 56.8 | 80.8 |
9 | 67 | Abdominal distension, Abdominalgia | 42.8 | 23.7 |
10 | 27 | No symptom | 18.4 | 19.5 |
Imaging examination results
No. | Age (years old) | Type | Surgical methods | Pathological type | Chemotherapy regimens | Follow-up |
---|---|---|---|---|---|---|
1 | 36 | Localized | Tumor cytoreductive surgery | Epithelioid type | No chemotherapy | Survived 109 m after surgery without tumor recurrence |
2 | 47 | Diffuse | Tumor cytoreductive surgery | Epithelioid type | (Pemetrexed + Cisplatin) *2 | Died 21 m after surgery |
3 | 56 | Diffuse | Partial tumor resection | Epithelioid type | (Pemetrexed + Cisplatin) *3 | Died 19 m after surgery |
4 | 68 | Diffuse | Partial tumor resection | Epithelioid type | (Pemetrexed + Cisplatin) *5 | Died 33 m after surgery |
5 | 67 | Diffuse | Tumor cytoreductive surgery | Epithelioid type | (Pemetrexed + Cisplatin) *2 | Died 17 m after surgery |
6 | 70 | Diffuse | Tumor cytoreductive surgery | Epithelioid type | Triplizumab *3 | Lost to follow-up |
7 | 69 | Diffuse | Tumor cytoreductive surgery | Epithelioid type | (Pemetrexed + Cisplatin) *6 | Survived, tumor recurrence |
8 | 65 | Diffuse | Partial tumor resection | Mixed | (Pemetrexed + Cisplatin) *4 | Died 22 m after surgery |
9 | 67 | Diffuse | Partial tumor resection | Epithelioid type | (Pemetrexed + Cisplatin + Bevacizumab) *3 | Survived, tumor recurrence |
10 | 27 | Localized | Tumor cytoreductive surgery | Epithelioid type | (Pemetrexed + Cisplatin + Bevacizumab) *2 | Survived without tumor recurrence |